Ascendis Pharma Financials - Benzinga

Ascendis Pharma AS

ASNDNASDAQ

Trade with Public

Trade with Public

$225.60

-5.10-2.21%

In chiusura: Sep 24, 5:00 PM EST

$225.60

-5.10-2.21%

Pre-mercato: 4:13 AM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Ascendis Pharma Financials

Ascendis Pharma (ASND) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.78 by 34.62 percent. This is a 212.9 percent increase over losses of $(0.93) per share from

Benzinga Newsdesk

PRO
Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 119.28 percent increase over losses of $(1.66) per share from

Benzinga Newsdesk

Ascendis Pharma Earnings Report: Q4 Overview

Benzinga Insights

PRO
Ascendis Pharma Q4 EPS $(0.64) Misses $(0.06) Estimate, Sales $288.127M Miss $289.720M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.06) by 966.67 percent. This is a 5.88 percent increase over losses of $(0.68) per share from

Benzinga Newsdesk

Earnings Scheduled For February 11, 2026

Benzinga Insights

A Glimpse of Ascendis Pharma's Earnings Potential

Benzinga Insights

© 2026 Benzinga | All Rights Reserved